Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables JW SH SC 512 1st Nov, 2024
3Q24 results: Within expectations
We believe the overall 3Q24 results were in line with our estimates. Historically, 4Q has contributed around 35-40% to the company's FY profit over the past five years, primarily driven by the annual rebates. While 3Q24 revenue grew strongly by +11% y-y, we estimate Alfamart's Same-Store Sales Growth (SSSG) to be at the lower end of the mid-to-high single-digit range. NPAT growth, at +5% y-y, appears weaker but is primarily due to one-time R&D income recognized in 3Q23 (IDR52bn). Excluding the one-time income, 3Q24 pre-tax profit still grew a respectable +12% y-y.
Although we acknowledge limited operating leverage improvements in 9M24, the company is investing in future efficiencies through additional chiller and cash deposit box machine initiatives. We believe these investments though create some margin pressure, will yield medium-to-long-term benefits for the company’s long-term margin improvement (read A consistent FMCG outperformer).
Ex-Java continues its stellar performance
3Q24 ex-Java sales grew impressively by +17% y-y (contributing 37% to revenue), significantly outpacing Java growth of +7% y-y (contributing 63% to revenue). This disparity likely explains why Alfamidi (MIDI IJ, Buy) outperformed AMRT's revenue growth in 3Q24, at +15% y-y, given Alfamidi's higher Java/Ex-Java split of 52/48. Notably, the Ex-Java region boasts a higher EBIT margin of 6.3% in 9M24 compared to Java's 4.6%. The faster growth in ex-Java underscores the company's focus on expanding further into this region. However, the Java region remains critical for AMRT, as it offers opportunities for higher rebates and operational efficiencies through the massive sales volume that they have.
Maintain Buy with TP of IDR3,830
We maintain our Buy call with TP of IDR3,830, pegged on a 2025F P/E of 33.4x, +1SD above its five-year average. We remain optimistic about AMRT's long-term margin improvement story, driven by industry duopoly and efficiency enhancements. We continue to view AMRT as the best proxy for Indonesia's FMCG-retail sector. Currently, the stock trades at 29x 2025F P/E.
Results recap
● 3Q24 revenue grew to IDR29tn (+11% y-y), bringing 9M24 revenue to IDR88tn (+10% y-y), in line with our/consensus' estimates.
● 3Q24 EBIT expanded +13% y-y to IDR687bn, bringing 9M24 EBIT to IDR2.8tn (+11% y-y), in line with ours but below consensus' estimates.
● 3Q24 NPAT reached IDR605bn (+5% y-y), bringing 9M24 NPAT to IDR2.4tn (+10% y-y), in line with our/consensus estimates.
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
Rating Remains | Buy |
Target price Remains | IDR 3,830 |
Closing price 31 October 2024 | IDR 3,320 |
Jody Wijaya (jody.wijaya@verdhana.id)
Sandy Ham (sandy.ham@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)